A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single- and Multiple-Ascending Doses and Food Effect of BGB-45035 in Healthy Participants and in Adults With Autoimmune Dermatological Diseases

NCT06342713 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

211

Enrollment

INDUSTRY

Sponsor class

Conditions

Healthy Participants
Healthy Subjects
Healthy Volunteers
Autoimmune Diseases
Healthy Adult Participants
Atopic Dermatitis
Prurigo Nodularis

Interventions

DRUG: BGB-45035
DRUG: Placebo

Sponsor

BeiGene